Ignite Creation Date:
2024-05-05 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 9:58 AM
Study NCT ID:
NCT00799032
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2008-11-25
Brief Title:
The ATLANTA First in Man Study of the Catania Stent
Sponsor:
CeloNova BioSciences Inc
Organization:
CeloNova BioSciences Inc
Study Overview
Official Title:
Assessment of The Latest Non-Thrombogenic Angioplasty Stent ATLANTA Prospective First in Man Non-Randomized Single Center for Patients With Documented Myocardial Ischemia Undergoing PCI
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATLANTA
Brief Summary:
To evaluate the short-term and mid-term safety and efficacy of the Catania coronary stent for the treatment of up to two de novo lesions in native coronary arteries
Detailed Description:
This is a prospective non-randomized first-in-man single center study The study requires a 55 patients with documented myocardial ischemia undergoing PCI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None